netFormulary Oxfordshire Clinical Commissioning Group NHS
Formulary  
 Search
 Formulary Chapter 5: Infections - Full Chapter
Chapter Links...
Link   UKMI Q&A: Cross-sensitivity between penicillins and cephalosporins
Link   UKMI Q&A: Penicillins and cephalosporins safety in breast feeding
 Details...
05.01  Expand sub section  Antibacterial drugs
 link Link    NICE CG64: Prophylaxis against infective endocarditis
 link Link    NICE NG15: Antimicrobial stewardship guideline
05.01  Expand sub section  Table 1. Summary of antibacterial therapy
05.01  Expand sub section  Table 2. Summary of antibacterial prophylaxis
05.01.01  Expand sub section  Penicillins
05.01.01.01  Expand sub section  Benzylpenicillin and phenoxymethylpenicillin to top
 link Link    UKMI Q&A: Syphilis treatment with parenteral benzylpenicillins
05.01.01.02  Expand sub section  Penicillinase-resistant penicillins
05.01.01.03  Expand sub section  Broad-spectrum penicillins
05.01.01.04  Expand sub section  Antipseudomonal penicillins
05.01.01.05  Expand sub section  Mecillinams
05.01.02  Expand sub section  Cephalosporins, carbapenems and other beta-lactums to top
05.01.02  Expand sub section  Cephalosporins
05.01.02.01  Expand sub section  Cephalosporins
05.01.02.02  Expand sub section  Carbapenems
05.01.02.03  Expand sub section  Other beta-lactums antibiotics
05.01.03  Expand sub section  Tetracyclines to top
05.01.03  Expand sub section  Tigecycline
05.01.04  Expand sub section  Aminoglycosides
05.01.05  Expand sub section  Macrolides
05.01.06  Expand sub section  Clindamycin
05.01.07  Expand sub section  Some other antibacterials to top
05.01.07  Expand sub section  Chloramphenicol
05.01.07  Expand sub section  Fosfomycin
05.01.07  Expand sub section  Fusidic acid
05.01.07  Expand sub section  Vancomycin and teicoplanin
05.01.07  Expand sub section  Daptomycin to top
05.01.07  Expand sub section  Linezolid
05.01.07  Expand sub section  Quinupristin and dalfopristin
05.01.07  Expand sub section  Polymyxins
05.01.07  Expand sub section  Rifaximin
05.01.07  Expand sub section  Fidaxomicin to top
05.01.08  Expand sub section  Sulphonamides and trimethoprim
05.01.09  Expand sub section  Antituberculosis drugs
 link Link    NICE CG33: Tuberculosis
 link Link    NICE NG33: Tuberculosis
05.01.10  Expand sub section  Antileprotic drugs
05.01.11  Expand sub section  Metronidazole and tinidazole
05.01.12  Expand sub section  Quinolones to top
05.01.13  Expand sub section  Urinary-tract infections
 link Link    NICE CG54: Urinary tract infection in children
 link Link    NICE CG97: Lower urinary tract symptoms in Men
 link Link    NICE therapeutic topic: Three-day courses of antibiotics for uncomplicated urinary tract infection
 link Link    OCCG leaflet: Patient information on UTIs in children
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
 Display tracking information
click to search medicines.org.uk
 Link to adult BNF
click to search medicines.org.uk
 Link to children's BNF
click to search medicines.org.uk
 Link to SPCs
SMC
 Scottish Medicines Consortium
Cytotoxic Drug
 Cytotoxic Drug
CD
 Controlled Drug
High Cost Medicine
 High Cost Medicine
Cancer Drugs Fund
 Cancer Drugs Fund
NHSE
 NHS England
Homecare
 Homecare
CCG
 CCG

Traffic Light Status Information

Status Description

Red

 Red: Medicines which should only be prescribed in secondary care by a specialist.  

Amber Continuation

Amber Continuation: Medicines which should be initiated or recommended by a specialist for continuation in primary care. The specialist must notify the GP that the prescribing responsibility has been transferred.   

Amber Shared Care Protocol

Amber Shared Care Protocol: Medicines which are appropriate to be initiated and stabilised by a specialist, once stabilised the medicine may be appropriate for responsibility to be transferred from secondary to primary care with the agreement of a GP and a formal ‘shared care’ agreement. The shared care protocol must be approved by the Area Prescribing Committee Oxfordshire (APCO).   

Green

 Green: Medicines which are suitable for initiation and ongoing prescribing within primary care.   

Brown

 Brown: Medicines which should only be prescribed in restricted circumstances.  

Black

 Black: Medicines which are not recommended for use because of lack of evidence of clinical effectiveness, cost effectiveness or safety.  

OCCG Green

 not used  

netFormulary